NuVasive To Expands Global Presence, Pediatric Portfolio With Ellipse Buy
This article was originally published in Clinica
Executive Summary
On Jan. 5, NuVasive said it agreed to buy Ellipse in a deal that is expected to be complete by the end of February. NuVasive will pay an additional $30 million in 2017 if Ellipse's portfolio meets certain revenue targets.
You may also be interested in...
Earnings Winners And Losers: BSX, BCR, NUVA, NVCR
Several big names in medtech announced their second-quarter sales and earnings in late July and early August. Here are some of the companies that impressed investors and others that raised some doubts.
Merck & Co. Files First IRA Suit, Signaling Industry Is Ready To Fight
Coming less than three months before the statutory deadline for CMS to publish the initial list of drugs, Merck’s lawsuit calls US Medicare drug price negotiations ‘extortion’ in a complaint that could be the first of more legal pushback to follow.